Type 1 Diabetes
An oral alternative for Type 1 Diabetes
In type 1 diabetes, the pancreas stops making insulin.
- Type 1 Diabetes (T1D) is an autoimmune disease that results in the destruction of the islet cells in the pancreas
- Insulin is the only effective treatment for T1D
- The goal of new treatments is to delay onset of disease and insulin treatment
- Most new treatments are expensive infusion or IV therapy
- About 30% of T1D patients avoid taking insulin shots because of fear of needles
- An oral therapy is needed, especially for the quality of life for the children diagnosed
- 12 Lipoxygenase uniquely drives both the innate and adaptive immune based destruction of the islet cells
- We have generated a 2nd generation inhibitor with superior IP, potency and oral availability that prevents the progression of the disease and rescues islet cells in both animal and human models
- There is a tremendous opportunity for an oral cost-effective alternative treatment for T1D patients and to reduce major complications of diabetes.
ALOX12 upregulated in human β islet cells of
T1D and T2D pancreas
LX12001 prevents the progression of T1D
and rescues β islet cells in human pancreas
- ALOX12 KO mice prevent T1D development.
- Specific inhibition of ALOX12 stops the progression of T1D and preserves beta islet cell function.
- Completed screening and ADMET studies for LX12001.